Nymox Pharmaceutical NX-1207 for BPH

On July 14, 2004 Nymox Pharmaceutical Corporation reported FDA approval for the NX-1207 clinical trial protocol for benign prostatic hyperplasia (BPH). In January 2004 the company had reported Phase I results which indicated that safety and tolerability data were sufficient for the company to move NX-1207 into Phase II testing. The recent FDA ruling has [...]

Matritech’s NMP179 for Detection of Cervical Cancer

On May 10, 2004 Matritech announced the beginning of clinical testing of 10,000 samples by Sysmex Corporation using NMP179 for the detection of women at risk of or with cervical cancer. The company reported that this novel strategy uses both Sysmex’s flow cytometry technology and Matritech’s NMP179 protein biomarker to perform rapid, cell-by-cell analysis for [...]